Xeris Biopharma Reports Record 2025 Performance, Achieves Profitability, and Issues Strong 2026 Revenue Guidance

summarizeSummary

Xeris Biopharma announced record Q4 and full-year 2025 financial results, achieving net income for the year and providing robust 2026 revenue guidance, signaling its emergence as a self-funding company.

check_boxKey Events

• Record 2025 Financial Performance

  The company achieved record quarterly total revenue of $85.8 million for Q4 2025 (up 42.8% year-over-year) and record full-year total revenue of $291.8 million for 2025 (up 43.7% year-over-year), driven by strong product sales, especially Recorlev.

• Achieved Full-Year Profitability

  Xeris Biopharma reported a net income of $11.1 million for Q4 2025 (compared to a net loss of $5.1 million in Q4 2024) and achieved a net income of $0.6 million for the full year 2025, a significant turnaround from a $54.8 million net loss in 2024. Adjusted EBITDA also improved significantly to $59.4 million for the full year.

• Robust 2026 Revenue Guidance

  The company provided full-year 2026 total revenue guidance in the range of $375 million to $390 million, representing over 30% growth at the midpoint compared to 2025, indicating strong projected continued momentum.

• Advancing Key Pipeline Asset

  Xeris Biopharma announced plans to initiate a Phase 3 clinical trial for XP-8121, a once-weekly subcutaneous injection for hypothyroidism, signaling progress in its development pipeline.

auto_awesomeAnalysis

This 8-K filing signals a significant positive inflection point for Xeris Biopharma. The company has successfully transitioned from a substantial net loss in 2024 to full-year profitability in 2025, driven by record revenue performance across its product portfolio, particularly Recorlev. The robust 2026 revenue guidance, projecting over 30% growth, underscores management's confidence in continued momentum and the company's stated emergence as a self-funding and sustainable biopharmaceutical entity. This financial strength is further supported by the planned advancement of its key pipeline asset, XP-8121, into Phase 3 clinical trials. Investors should view these results and outlook as a strong validation of the company's commercial strategy and operational execution, significantly de-risking its financial profile and enhancing its long-term value proposition.